2cureX’s CEO Ole Thastrup will join Folkemødet 2018 in Denmark
2cureX AB (“2cureX”) is invited by Bristol-Meyers Squibb Denmark to participate in a panel discussion at ”Folkemødet 2018” with amongst others the Minister of Industry, Business and Financial Affairs, Brian Mikkelsen. The panel discussion will focus on Innovation in Life Science and how to stimulate entrepreneurship and collaboration with academia to create the employers of the future. Folkemødet will be held in Allinge, Bornholm from June 14th to June 17th with the purpose of offering a democratic dialogue between politicians and stakeholders representing a broad spectrum of interest groups.
2cureX managed a successful IPO at Nasdaq First North in Stockholm November 24th 2017 and is preparing to launch its proprietary technology IndiTreat® in the Nordics, the United Kingdom and Germany. CEO Ole Thastrup says; “We feel honored to be seen as one of the new innovative Bio-Tech companies and to share our experience and best practices in building 2cureX, in order to help define prerequisites that will increase innovation and business opportunities within the Life Science sector”
The Danish Folkemødet is organized by Foreningen Folkemødet and participation is free. For further information, please visit https://folkemoedet.dk/
Sedermera Fondkommission is the Certified Adviser of 2cureX.
For more information about 2cureX:
Ole Thastrup, CEO
Phone: +45 22 11 53 99
2cureX has developed IndiTreat® (Individual Treatment Design) – a patented method for selecting the right drug for the right patient, thereby improving cancer treatment. Initially, IndiTreat® is targeted towards colorectal cancer; but the method is applicable to additional cancer indications (e.g. ovarian, breast and kidney cancer). The company is listed at the Nasdaq First North stock exchange in Stockholm (symbol “2CUREX”).